According to the previous interim analysis, the number of patients receiving advanced therapy, other than anti-TNFα antibody agents was small; therefore, the risk of COVID-19 severity for patients prescribed such agents could not be examined in detail.13 This evidence concerns the gene TNF and COVID-19.